imfinzi - durvalumab injection, solution
(Durvalumab)Astrazeneca Pharmaceuticals Lp
Usage: Imfinzi is a PD-L1 antibody indicated for adults with NSCLC (resectable, unresectable Stage III, or metastatic), limited- and extensive-stage SCLC, biliary tract cancer, unresectable hepatocellular carcinoma, dMMR endometrial cancer, muscle-invasive bladder cancer, and resectable gastric/GEJ adenocarcinoma. Administered as monotherapy or with chemotherapy.